- Home
- SMX vs KLTO Comparison
SMX vs KLTO Comparison
Compare SMX & KLTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SMX
- KLTO
- Stock Information
- Founded
- SMX N/A
- KLTO 2019
- Country
- SMX Ireland
- KLTO United States
- Employees
- SMX N/A
- KLTO N/A
- Industry
- SMX Industrial Machinery/Components
- KLTO
- Sector
- SMX Technology
- KLTO
- Exchange
- SMX Nasdaq
- KLTO NYSE
- Market Cap
- SMX 6.7M
- KLTO 5.9M
- IPO Year
- SMX N/A
- KLTO N/A
- Fundamental
- Price
- SMX $1.25
- KLTO $0.92
- Analyst Decision
- SMX
- KLTO
- Analyst Count
- SMX 0
- KLTO 0
- Target Price
- SMX N/A
- KLTO N/A
- AVG Volume (30 Days)
- SMX 11.1M
- KLTO 5.9M
- Earning Date
- SMX 01-01-0001
- KLTO 08-15-2025
- Dividend Yield
- SMX N/A
- KLTO N/A
- EPS Growth
- SMX N/A
- KLTO N/A
- EPS
- SMX N/A
- KLTO N/A
- Revenue
- SMX N/A
- KLTO N/A
- Revenue This Year
- SMX N/A
- KLTO N/A
- Revenue Next Year
- SMX N/A
- KLTO N/A
- P/E Ratio
- SMX N/A
- KLTO N/A
- Revenue Growth
- SMX N/A
- KLTO N/A
- 52 Week Low
- SMX $1.06
- KLTO $0.11
- 52 Week High
- SMX $846.56
- KLTO $3.91
- Technical
- Relative Strength Index (RSI)
- SMX 31.72
- KLTO N/A
- Support Level
- SMX $1.48
- KLTO N/A
- Resistance Level
- SMX $3.32
- KLTO N/A
- Average True Range (ATR)
- SMX 0.40
- KLTO 0.00
- MACD
- SMX 0.07
- KLTO 0.00
- Stochastic Oscillator
- SMX 8.41
- KLTO 0.00
About SMX SMX (Security Matters) Public Limited Company
SMX (Security Matters) PLC provides one solution to solve both authentication and track and trace challenges in order to uphold supply chain integrity and provide quality assurance and brand accountability to producers of goods. Its technology works as a track and trace system using a marker, a reader, and an algorithm to identify embedded sub-molecular particles in order to track and trace different components along a production process (or any other marked good along a supply chain) to the end producer.
About KLTO KLOTHO NEUROSCIENCES INC
Klotho Neurosciences Inc is in the development of essential medicines for the treatment of chronic diseases: Cancer, Cardiovascular, and Neurodegenerative disorders. The Company currently has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and a proprietary, patented gene therapy platform which uses a gene therapy approach to introduce a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases. Company pipeline includes KLTO 101, KLTO 202, KLTO 301.